BioCentury
ARTICLE | Clinical News

Ovid reports Phase I data for CYP46A1 inhibitor OV935

January 5, 2018 9:55 PM UTC

Ovid Therapeutics Inc. (NASDAQ:OVID) reported data from a pair of Phase I trials in 88 healthy volunteers showing that single ascending doses of up to 1,350 mg and multiple ascending doses of up to 400 mg OV935 (TAK-935) were well tolerated. The company is evaluating the candidate to treat developmental and epileptic encephalopathies. Data were presented at the American Epilepsy Society meeting in Washington, D.C.

The double-blind, placebo-controlled, U.S. trials evaluated safety and pharmacokinetics of the cytochrome P450 family 46 subfamily A polypeptide 1 (CYP46A1; CH24H) inhibitor...